R&D PIPELINE THERAPY AREAS

R&D Pipeline Therapy Areas

The agents and uses mentioned below are investigational and have not been approved by the US Food and Drug Administration (FDA) for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents and uses.
Sanofi’s oncology pipeline strategy is to leverage new technologies empowering molecular oncology, immune-oncology, and genomic medicine platforms with a focus on multiple myeloma (MM) and other blood cancers, as well as lung cancers.

Latest News from Sanofi

New data from Sanofi’s oncology pipeline and portfolio to be presented at ASCO 2023

Educational Resources

General

Pre-approval Information Exchange: Overview of the Sanofi Specialty Care Pipeline
A presentation providing a brief general overview of Sanofi’s specialty care R&D pipeline, including investigational agents and proposed mechanistic targets in Multiple Myeloma. All information is updated quarterly.

Multiple Myeloma

Pre-approval Information Exchange: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed, Transplant-eligible Multiple Myeloma: Post Transplantation Interim Analysis of the Randomized Phase 3 GMMG-HD7 Trial
A presentation summarizing the study design and interim analysis of the Phase 3 GMMG-HD7 study which investigates the efficacy and safety profile of the quadruplet combination of isatuximab with RVd (Isa-RVd, isatuximab combined to lenalidomide, bortezomib, and dexamethasone) versus RVd (lenalidomide, bortezomib, and dexamethasone) induction followed by post-transplant re-randomization to Isa-R maintenance in transplant eligible newly-diagnosed multiple myeloma (NDMM) patients. These data were presented as an oral presentation (abstract #S202) at the 2024 European Hematology Association (EHA 2024).

GMMG-HD7: NCT03617731; Link to Publication